The fetus is supplied from the placenta with estradiol (E 2 ) and progesterone (P) in increasing amounts during gestation. After delivery of a premature infant, placental supply is disrupted, resulting in a rapid decrease in E 2 and P. Replacement of these placental hormones may restore intrauterine conditions and may be beneficial for bone mineral accretion, clinical course, and outcome. Thirty female infants with a median gestational age of 26.6 weeks (between 24.1-28.7) and a birth weight of 675 g (370 -990) were randomized to receive E 2 and P replacement, aiming to maintain plasma levels equaling the intrauterine levels, or no replacement. The E 2 and P replacement was started iv and was followed by transepidermal administration for a total duration of 6 weeks. Repeated measurements included plasma levels of E 2 , P, FSH, and LH; uterine volume; calcium and phosphorus in spot urine specimens; and bone mineral accretion by single photon absorption densitometry. Further, the incidence of chronic lung disease and various clinical outcome data were recorded. The plasma levels of E 2 and P were within the intrauterine range with median replacements of 2.30 mg/kg⅐day E 2 (1.13-6.23) and 21.20 mg/kg⅐day P (11.23-27.36), iv. Three-and 6-fold higher doses of E 2 and P were needed via the transepidermal route. The uterine volumes increased, and FSH and LH as indicators for biological effectiveness were significantly lowered with replacement. The bone mineral accretion rates tended to be higher, and the incidence of chronic lung disease tended to be lower (0% vs. 29%; P ϭ 0.097). E 2 and P replacement via iv and transepidermal routes is capable of maintaining plasma levels as high as those in utero with biological effectiveness. Trends toward improved postnatal bone mineral accretion and less chronic lung disease were found with the hormone replacement. Further and more extensive studies are warranted to address the role of this new approach in the care of extremely premature infants. (J Clin Endocrinol Metab 84: [4531][4532][4533][4534][4535] 1999) 
D
URING PREGNANCY 17␤-estradiol (E 2 ) and progesterone (P) plasma levels rise up to 100-fold in the mother (1) . The determination of E 2 and P in umbilical cord blood at different gestational ages has shown that the fetus is exposed to the same increasing levels. Within 1 day following delivery the levels of E 2 and P drop by a factor of 100 in both the mother and the infant. Extremely low birth weight infants experience this deprivation much earlier than infants born at term. Nothing is known about the consequences of this deprivation of E 2 and P at this early developmental stage.
It is generally accepted that estrogens and progestins have important impacts on bone metabolism (2, 3) . However, to our knowledge there have been no studies published concerning the role of sex steroids in the postnatal bone mineralization of extremely low birth weight infants. Parallel to postmenopausal osteoporosis that is related to E 2 deficiency (2), deprivation of the placental supply of E 2 and P may contribute to the postnatal bone deficiency found in extremely low birth weight infants, known as the osteopenia of prematurity (4, 5) .
Extremely low birth weight infants are prone to develop respiratory distress syndrome due to the deficient production of surfactant by alveolar type II cells (6) . Respiratory insufficiency requires mechanical ventilation, and this may contribute to the development of chronic lung disease (7) . The results of animal studies suggest that estrogens may play a role in fetal lung maturation and surfactant production (8) . Therefore, a postnatal replacement of E 2 and P may influence the incidence of chronic lung disease.
Placental function and fetal growth are well correlated, suggesting that the placenta plays a key role in the regulation of fetal growth (9) . Interruption of intrauterine growth after extremely preterm birth can have long term negative effects on growth (10) . E 2 and P are major metabolic products of the placenta during mid-and late gestation. Would the replacement of these two hormones have an effect on postnatal growth in extremely low birth weight infants?
The aim of the present controlled randomized pilot study was to test the hypothesis that E 2 and P replacement therapy improves postnatal bone mineral accretion. The clinical course and outcome data, e.g. incidence of chronic lung disease and postnatal growth, were also recorded.
Subjects and Methods Subjects
Female infants with a gestational age of less than 29 weeks and a birth weight of less than 1000 g were eligible, as long as written informed consent was given by the parents. Only female infants were studied, because uterine growth was selected as the indicator for the biological effectiveness of the E 2 and P replacement. Infants were randomized into two groups. One group received E 2 and P replacement (replacement group), and the infants of the other group served as controls (control group). The study was approved by the institutional review board of the University of Ulm.
Methods
This pilot study was designed as a randomized trial without sample size calculation. E 2 , P, FSH, and LH plasma levels were measured in mixed umbilical cord blood and in blood samples drawn at 24 and 72 h on the fifth and seventh days, once a week until the seventh postnatal week, and during the ninth postnatal week. In the control group the weekly blood samples were restricted to the fourth and ninth weeks. Commercially available enzyme immunoassays (Enzymun-Test, Roche Molecular Biochemicals, Mannheim, Germany) were used. The method and accuracy of the E 2 enzyme immunoassay have been described previously (11) . E 2 and P plasma levels were available from the laboratory within 4 h. Thereafter, the replacement therapy was adjusted to maintain plasma levels of 2000 -6000 pg/mL E 2 (7.34 -22 .03 nmol/L) and 300 -600 ng/mL P (0.95-1.91 mol/L), which correspond to the intrauterine levels (12) (13) (14) (15) (16) (17) (18) .
The bone mineral content was measured within the first week of life and at the end of the replacement period using single photon absorption densitometry (model 278/C, Norland Corp., Fort Atkinson, WI). Three to five scans were performed at the midhumerus without repositioning. The coefficient of variation is approximately 3% (19) . The bone mineral accretion (milligrams per cm/100 g) was calculated as the difference between the two bone mineral content measurements divided by the weight gain. The parenteral and enteral mineral supplementations were individually adjusted, as described previously in detail (20) . The supplementation was classified as sufficient if calcium levels of 1.2 mmol/L or more and phosphorus levels of 0.4 mmol/L or more were excreted simultaneously in 50% or more of all individual spot urine specimens taken twice weekly during the first 6 weeks. This classification was used to build subgroups with sufficient and insufficient mineral supplementation.
Postnatal somatic growth was determined once a week. The changes in body weight and body length were reported as relative increases related to the values obtained the week before.
The anteroposterior (H) and horizontal (W) diameters of the cervix and uterine length (L) from the top of the fundus to the bottom of the cervix were measured by ultrasound within the first week of life and after 3, 6, and 9 weeks. The uterine volume was estimated as H ϫ W ϫ L ϫ 0.5.
The need for mechanical ventilation, surfactant, oxygen, and dexamethasone therapy and the rate of chronic lung disease (defined as requirement for additional oxygen later than the 36th week of postmenstrual age) were recorded.
E 2 and P replacement
17␤-E 2 [estra-1,3,5(10)-triene-3,17␤-diol, Fa. Synopharm, Hamburg, Germany) and P (pregn-4-ene-3,20-dione, Synopharm) diluted in 98% ethanol were added to a phospholipid-stabilized soybean oil emulsion (Intralipid, Pharmacia & Upjohn, Inc., Erlangen, Germany) used for parenteral nutrition. Several solutions were produced containing 0.05 g/mL fat, between 2.2 ng/mL and 0.22 mg/mL E 2 , and between 0.4 -1250 g/mL P (E 2 -P-lipid-5% mixture). In the replacement group constant and continuous 24-h iv infusion of the E 2 -P-lipid-5% mixture (median, 19.2 mL/kg⅐day; 10.9 -32 minimum and maximum) was started after birth as soon as venous access was obtained. The control group received 15 mL/kg⅐day of an E 2 -and P-free lipid-5% mixture. The E 2 and P replacement was continued for 6 weeks. If venous access was no longer indicated, E 2 and P were administered transepidermally by means of an ointment. Ointments were prepared on the basis of lanolin alcohol, cetearyl alcohol, petrolatum, and propylene glycol containing 4.5-46 mg/mL E 2 and 114 -284 mg/mL P. The E 2 concentrations were thus much higher than those in commercially available gels for postmenopausal use (0.6 mg/mL). Ointment doses were measured with a 1-mL syringe, and one to three doses (median, 0.50 mL/kg⅐day; 0.14 -1.0) were applied to the abdominal skin and to the back (lumbar region), wearing gloves.
Statistical analysis
The Mann-Whitney U test was used to compare the results of the study groups. P Ͻ 0.05 was considered significant.
Results
During the enrollment period, 40 female infants with a gestational age of less than 29 weeks and a birth weight of less than 1000 g were treated at the study center. Of these, 10 infants were not included in the study because informed consent from the parents was not given or not possible within the first day. From the remaining 30 infants, 15 were enrolled in each group. The characteristics of the 2 groups are shown in Table 1 . Twenty-five (83%) of the enrolled infants survived. In the replacement group 2 infants died on the first postnatal day from septic shock and severe respiratory distress syndrome, respectively. In the control group 1 infant died at the age of 3 days from untreatable arterial hypotension. The other 2 control group infants died at the ages of 71 and 282 days from unexplained hepatopathy and severe bronchopulmonary dysplasia, respectively.
The median duration of the iv replacement of E 2 and P was 20 days (12-44, minimum and maximum). Plasma levels of E 2 and P were within the target ranges of 2000 -6000 pg/mL E 2 and 300 -600 ng/mL P with a median dose of 2.30 mg/ kg⅐day E 2 (1.13-6.23 mg/kg⅐day) and 21.20 mg/kg⅐day P (11.23-27.36 mg/kg⅐day). Median doses of 6.68 mg/kg⅐day E 2 (2.77-11.55) and 132.8 mg/kg⅐day P (85.5-238) were used via the transepidermal route. From all E 2 and P plasma levels measured at the defined time points, 66% and 47% exceeded the lower target limits for E 2 and P during iv replacement, respectively. During transepidermal replacement, 45% and 27% of E 2 and P plasma levels exceeded the lower target limit, respectively. Figure 1 shows the E 2 and P plasma levels of both groups at the different time points.
Uterine volumes of the replacement group increased significantly during the replacement period toward the level of volumes found in newborn infants born at term and decreased after the replacement was stopped (Fig. 2) . The uterine volumes of the control group remained significantly lower than those of the replacement group. Plasma levels of FSH and LH in the replacement group remained on a significantly lower level for the entire replacement period and increased thereafter (Table 2 ). At 9 weeks both groups showed similar levels. The infants were divided into the subgroups defined in Materials and Methods. The median bone mineral accretion rates (with minimum and maximum) in the four subgroups are listed in Table 3 . The highest bone mineral accretion rates were found in the replacement group when mineral supplementation was sufficient.
In the replacement group, 9 of 13 (69%) infants were intubated compared with 11 of 14 (79%) in the control group. There was no difference between the groups in the type of ventilation used (high frequency ventilation, conventional ventilation, or both) or in the use of prenatal betamethasone for respiratory distress syndrome prophylaxis (Table 1) . Seven (77%) infants of the replacement group and 9 (81%) infants of the control group received bovine surfactant. Dexamethasone to facilitate weaning/extubation and to prevent chronic lung disease was given to 3 (23%) infants in the replacement group compared with 7 (50%) in the control group. No infant in the replacement group developed chronic lung disease, but 4 (29%) in the control group did (P ϭ 0.097).
The median weekly percent increases in body weight and body length were 11.2% (minimum and maximum, Ϫ14 to 32) and 2.8% (Ϫ5.9 to 15) for the replacement group and 9.8% (Ϫ13 to 30) and 2.2% (Ϫ2.6 to 14) for the control group (P ϭ 0.47 and 0.92), respectively. They remained below the median intrauterine increases of 12.3% and 3.8% for body weight and body length that were calculated from the 50th percentile of intrauterine growth curves (21) . Survival, morbidity data, and age and weight at discharge home are shown in Table 4 . No significant differences between the groups were found.
Discussion
Currently there is no study available examining the subsequent effects of early withdrawal from the placental supply of E 2 and P on extremely preterm infants. To our knowledge, this is the first investigation which has studied the effects of placental hormone replacement therapy with E 2 and P. This study was designed as a pilot study with low set numbers of patients because there was no experience with an E 2 and P replacement in extremely low birth weight infants to draw upon.
We were able to demonstrate that intrauterine plasma levels of E 2 and P can be maintained by constant and continuous iv application of an E 2 -P-lipid 5% mixture started within the first postnatal hours. The transepidermal administration of E 2 and P by means of an ointment resulted less frequently in the desired E 2 and P plasma concentrations and needs further improvement. Basic considerations about doses, iv preparations, and target plasma levels of E 2 and P have recently been described in detail (11) .
During pregnancy, the uterus of the female fetus grows (22) . After birth, uterine size decreases to its prepubertal size within the first year of life (23, 24) in accordance with the postnatal drop in plasma E 2 levels. We found that during E 2 and P replacement, uterine volumes of the extremely preterm infants increased as they did in utero. As expected FSH and LH plasma levels remained suppressed during the E 2 and P replacement period. The well known postnatal increase in FSH and LH that was seen in the control group occurred in the replacement group after the replacement had been stopped. These results provide evidence for the biological effectiveness of the E 2 and P replacement.
In vitro studies on cultured fetal mouse bones demonstrate a dose-dependent stimulatory effect of E 2 on bone formation and mineralization (25) . Fetuses showed increased skeletal calcification after the pregnant mice had received varying doses of the synthetic estrogen diethylstilbestrol. Moreover, estrogen treatment in this early phase of fetal bone tissue development resulted in higher calcium contents and mineral apposition rates in adulthood compared with those in controls. This finding suggests an estrogen-imprinting effect on bone cell programming in fetal life (26) . Therefore, it is conceivable that early deprivation of E 2 in extremely low birth weight infants may have long term impact on bone FIG. 1. Plasma levels of E 2 and P in preterm infants with (F) and without (E) replacement of E 2 and P at different postnatal ages. Medians and 10th and 90th percentiles (conversion factors to Systeme International units: E 2 , 3.67; P, 3.18). The dotted lines indicate the desired plasma levels of E 2 and P. The E 2 and P replacement period is indicated by the horizontal bar on the top of the figure. mineralization. Intrauterine bone mineral accretion approximates 4.5 mg/cm⅐100 g wt gain (19, 27) . It has been shown that intrauterine bone mineral accretion can be achieved by individually adjusted mineral supplementation (20) . However, even if vitamin D and mineral supplementations are adequate, postnatal bone mineral accretion rates can lag behind the intrauterine rate. In our study the highest bone mineral accretion rates were found in infants with hormone replacement. As a group, those infants achieved the highest mineral accretion rates who were provided with both hormones and sufficient quantities of minerals. Bone mineral accretion of the control group was not affected by sufficient mineral supplementation. These results support our speculation that osteopenia of prematurity is not only dependent on mineral supply but may also reflect E 2 and P deficiency.
Administration of E 2 to pregnant rabbits increased the phospholipid and phosphatidylcholine content and the phosphatidylcholine/sphingomyelin ratio of fetal rabbit lung lavage, suggesting increased fetal lung maturation and surfactant production (8) . Increases in alveolarization, num- The groups were divided into subgroups with sufficient and insufficient mineral supplementation (n, medians, with minimum and maximum in parentheses). No significant differences between the subgroups were found (by Mann-Whitney U test). Insufficient: calcium, Ն1.2 mmol; phosphorus, Ն0.4 mmol/L in less than 50% of urine specimens; sufficient: calcium, Ն1.2 mmol; phosphorus, Ն0.4 mmol/L in 50% or more of urine specimens. (28, 29) . Furthermore, messenger ribonucleic acid levels of surfactant protein A and B in fetal rabbit lung cells are enhanced by maternal E 2 administration (30) . A lower rate of respiratory distress syndrome was found after a single im injection of aqueous estrogens immediately after birth (31) . In our study the needs for intubation and surfactant therapy were similar in the two groups. Nevertheless, no infant in the replacement group developed chronic lung disease compared with 29% in the control group who did. The reviewed literature and the results of the study emphasize a possibly important role of E 2 and P for lung function and lung maturation. Because chronic lung disease is a major determinant of postnatal morbidity and mortality in extremely low birth weight infants, postnatal E 2 and P replacement may be promising.
Placental GH in the maternal circulation is significantly reduced in cases of intrauterine growth retardation (32) . The somatotropic effects of placental GH on fetal growth seem to be mediated through the induction of insulin-like growth factor I (33). In baboon pregnancy, E 2 increases the maternal plasma levels of placental GH (34) . Therefore, E 2 and P do not appear to have a direct role in the regulation of growth, but may act in utero via the regulation of placental somatotropic agents. Preterm delivery means loss of the placenta as a possible mediator of the effects of E 2 on growth. The finding that the median percent increases in body weight and body length of the replacement group were below the intrauterine increases is in accordance with these considerations.
Our study, with its small number of infants, has a pilot character. It demonstrates that it is feasible postnatally to maintain the high intrauterine plasma levels with significant biological effectiveness in infants born very prematurely. No negative side-effects attributable to the E 2 and P replacement were observed. Infants with E 2 and P replacement showed trends toward improved bone mineral accretion if mineral supplementation was sufficient and toward reduced incidence of chronic lung disease. These promising results warrant further studies to address the role of this new approach in the care of infants born extremely prematurely.
